



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, C12N 1/12, 1/20, C12Q 1/02		A1	(11) International Publication Number: WO 99/08532
			(43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/14793 (22) International Filing Date: 17 July 1998 (17.07.98) (30) Priority Data: 08/910,850 13 August 1997 (13.08.97) US (71) Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; DW Brooks Drive, Athens, GA 30602 (US). (72) Inventors: DOYLE, Michael, P.; 107 Stonington Drive, Peachtree City, GA 30269 (US). ZHAO, Tong; 206 Mor- gan's Turn, Peachtree City, GA 30269 (US). HARMON, Barry, G.; 110 Hillsborough Drive, Athens, GA 30606 (US). BROWN, Cathy, Ann; 165 Hanover Drive, Bogart, GA 30622 (US). (74) Agents: GREENLEE, Lorraine, L. et al.; Suite 201, 5370 Manhattan Circle, Boulder, CO 80303 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: CONTROL OF ENTEROHEMORRHAGIC <i>E. COLI</i> O157:H7 IN CATTLE BY PROBIOTIC BACTERIA			
(57) Abstract			
<p>Dominant probiotic bacterial strains have been isolated. The isolated bacterial strains fed to a ruminant animal are able to prevent the establishment of the pathogen <i>E. coli</i> O157:h7 in the animal. The strains can be re-isolated from the gastrointestinal tract contents of inoculated animals at about 28 days post-inoculation. Animals previously infected by <i>E. coli</i> O157:h7 can be treated to reduce or eliminate the pathogen by administering any of the dominant probiotic bacteria of the invention.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	NO	Norway	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

CONTROL OF ENTEROHEMORRHAGIC *E. COLI* O157:H7
IN CATTLE BY PROBIOTIC BACTERIA

STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH AND DEVELOPMENT

Research underlying the invention was carried out in part with support of Grant No. 97-433 from the United States Department of Agriculture. The U.S. Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

E. coli O157:H7, an important human pathogen causing hemorrhagic colitis and hemolytic uremic syndrome, has been reported with increased frequency during the past decade as a cause of human illness [for reviews, see Bell, P.B., et al. (1994) *JAMA* 272:1349-1353; Griffin, P.M. et al. (1991) *Epidemiol. Rev.* 13:60-98; Padhye, N.Y. et al. (1992) *J. Food Prot.* 55:555-565]. Cattle, especially young animals, have been implicated as a principal reservoir of *E. coli* O157:H7, with undercooked ground beef being a major vehicle of foodborne outbreaks. Also, the number of fruit-, fruit juice-, vegetable- (lettuce) and water- (including recreational lakes) related outbreaks have increased dramatically in recent years.

A recent national survey performed by the USDA National Animal Health Monitoring System revealed that 1.6% of feedlot cattle fecally shed *E. coli* O157:H7 and 0.4% shed *E. coli* O157:NM [Dagatz, D. (1995) USDA:APHIS:VS, Centers for epidemiology and animal health. Fort Collins, CO (personal communication)]. A major study of calves on dairy farms revealed that 1.5% that were between the age of weaning and 4 months shed *E. coli* O157:H7 in their feces [Zhao, T., et al. (1995) *Appl. Environ. Microbiol.* 61:1290-1293]. Experimental infection of calves and adult cattle with *E. coli* O157:H7 varies widely among animals of the same age group, but persists longer in calves than in adults and previous infection does not prevent reinfection by the same strain of *E. coli* O157:H7 [Cray, CW. et al. (1995) *Appl. Environ. Microbiol.* 61:1585-1590]. Other animals, such as chickens, deer, and sheep have also been determined to have the ability to carry *E. coli* O157:H7 for an extended period of time.

Many public health concerns have been raised regarding *E. coli* O157:H7 contamination of foods. Such concerns have been heightened by the unique acid tolerance of *E. coli* O157:H7. Proper cooking is an effective method to kill *E. coli* O157:H7 in foods. However, insanitary practices in preparing foods often result in foodborne illness,

hence methods to reduce or eliminate carriage of *E. coli* O157:H7 in cattle are needed to reduce the public's exposure to the pathogen in food and the environment [Wang, G., et al. (1996) *Appl. Environ. Microbiol.* 62:2567-2570].

Vaccination has been the traditional approach to protecting cattle from carriage of harmful bacteria. However, *E. coli* O157:H7 does not adhere to or infect cattle. The primary sites of *E. coli* O157:H7 localization in calves are the rumen and colon. The rumen appears to be the most important site for long-term carriage of *E. coli* O157:H7, and may serve as the source of bacteria found in the colon [Brown, C., et al. (1995) *Vet. Pathol.* 32:587]. Histologic examination of colon tissue revealed no evidence of attachment of *E. coli* O157:H7 to colon tissue. Hence, the presence of *E. coli* O157:H7 in the colon appears to be a transient state whereby the bacteria are passing through, rather than colonizing the colon. Vaccines are not likely to be effective in reducing the amount of *E. coli* O157:H7 carried and shed by cattle.

The amount of *E. coli* O157:H7 carried by calves can be affected by nutrition and management practices. Rasmussen, et al. [(1993) *FEMS Microbiol. Lett.* 114:79-84] determined that *E. coli* O157:H7 grew unrestricted in rumen fluid collected from fasted cattle.

Some strains of *E. coli* can produce colicins that are inhibiting *in vitro*, to diarrheagenic *E. coli* strains, including strains of serotype O157:H7 [Bradley, D. E., et al. (1991) *Can J. Microbiol.* 37:97-104; Murinda, S.E., et al. (1996) *Appl. Environ. Microbiol.* 62:3196-3202]. Murinda et al. assayed twenty-four *E. coli* colicin-producing strains and determined that all *E. coli* O157:H7 strains evaluated were sensitive to Col EI to E8,K and N on mitomycin-C-containing agar and also to Col G, Col. H and MccB17 on Luria agar. Patterns of colicin-sensitivity and resistance have been used for strain identification. Biological control of a bacterial strain based on its bacteriocin-sensitivity has not been achieved. However, Doyle, et al. U.S. Patent 5,302,388, disclosed prevention or inhibition of *Campylobacter jejuni* colonization of poultry by administering a selected bacterial strain capable of competing with *C. jejuni* for colonization sites in poultry cecum and of inhibiting growth of *C. jejuni*.

SUMMARY OF THE INVENTION

The present invention includes specific strains of probiotic *E. coli*, their isolation, characteristics and methods of use to prevent or treat *E. coli* O157:H7 carriage by a

5 ruminant animal. By "probiotic" is meant bacteria having the property of preventing establishment of *E. coli* O157:H7 in a ruminant animal previously administered an effective dose of said probiotic bacteria. For example, calves first administered an effective amount of a strain of probiotic bacteria then subsequently administered *E. coli* O157:H7 do not become carriers of *E. coli* O157:H7, while calves administered only *E. coli* O157:H7 continue to carry the strain for weeks, shedding the bacteria to the environment in feces. Of eighteen probiotic strains isolated in the present study, four were identified as "dominant" by which is meant that they could be reisolated from the gastrointestinal tract contents of inoculated animals at about 28 days post-inoculation.

10 Dominant probiotic bacteria were also shown to be capable of reducing or eliminating the *E. coli* O157:H7 from calves previously inoculated with *E. coli* O157:H7 and carrying the pathogen.

The invention therefore provides a method for preventing the carriage of *E. coli* O157:H7 by a ruminant by the step of administering an effective amount of a strain or combination of strains of probiotic bacteria to the ruminant prior to exposure to *E. coli* O157:H7. The method is especially useful for treating young ruminants, such as bovine calves, at an early age, before exposure to *E. coli* O157:H7 which may be present in the environment. The method is also useful to prevent animals shipped to a feedlot from being contaminated at the feedlot.

20 The invention further provides a method for reducing or eliminating *E. coli* O157:H7 from a ruminant by administering an effective amount of a strain or combination of strains of dominant probiotic bacteria. The method is useful to maintain cattle herds free of *E. coli* O157:H7 and to reduce carriage of *E. coli* O157:H7 prior to slaughter.

25 The administration of probiotic bacteria is accomplished by feeding a feed supplement or additive which comprises an effective amount of probiotic bacteria, or by supplying a water treatment additive or inoculum to the animals' drinking water. The invention therefore provides a feed supplement composition comprising probiotic bacteria, and a water additive comprising probiotic bacteria.

30 The invention further includes a method for isolating probiotic bacteria which includes screening the growth supernatant of strains isolated from feces or intestine for ability to inhibit growth of *E. coli* O157:H7 on agar. A method for identifying dominant probiotic bacteria includes the step of inoculating a ruminant animal with a mixture of

probiotic bacterial strains, then isolating the strains from the animal after a defined time period, for example, about 4 weeks. The reisolated strains are those which have successfully persisted in the animal, hence the term dominant probiotic bacteria. Reisolation and identification of dominant probiotic strains can be facilitated by the use of marker traits, either endogenous, selected or engineered, which allow each strain to be identified and/or selected from a mixture.

The methods for isolating probiotic bacteria, for isolating dominant probiotic bacteria, for preventing the carriage of *E. coli* O157:H7 and for treating an animal to reduce or eliminate *E. coli* O157:H7 from the animal are all applicable to other animals besides cattle, especially other ruminants, which have also been observed to carry *E. coli* O157:H7. At present, cattle are the most numerous carriers of *E. coli* O157:H7. The methods of isolation and use of dominant probiotic strains are accomplished by studies carried out with cattle. A large number of strains is available from natural sources which can meet the criteria of probiotic, and dominant probiotic bacteria. Repetitions of the herein-described isolation process may yield the same or different strains than those described herein. Such strains fall within the general categories of probiotic and dominant probiotic bacteria, as herein described.

DESCRIPTION OF THE DRAWINGS

Fig. 1. is a graph showing the fate of *E. coli* O157:H7 in rumen fluid of calves administered only *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 2. is graph showing the fate of *E. coli* O157:H7 in feces of calves administered only *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 3. is a graph showing the fate of *E. coli* O157:H7 in rumen fluid of calves administered probiotic bacteria and 2 days subsequently *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 4. is a graph showing the fate of *E. coli* O157:H7 in feces of calves administered probiotic bacteria and 2 days subsequently *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 5. is a graph of the fate of *E. coli* O157:H7 in rumen fluid of calves administered *E. coli* O157:H7 only. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 6. is a graph of the fate of *E. coli* O157:H7 in feces of calves administered *E. coli* O157:H7 only. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 7. is a graph of the fate of *E. coli* O157:H7 in rumen fluid of calves treated with dominant probiotic bacteria 1 to 3 days after administration of *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 8. is a graph of the fate of *E. coli* O157:H7 in feces of calves treated with dominant probiotic bacteria 1 to 3 days after administration of *E. coli* O157:H7. Arrow indicates detection of *E. coli* O157:H7 only by an enrichment procedure.

Fig. 9. profiles XbaI digests of genomic DNA of dominant probiotic bacteria by pulsed-field gel electrophoresis. Both left and right lane are λ ladders (48.5kb). Lanes 1 to 8 are strain 271.

Fig. 10. profiles XbaI digests of genomic DNA of dominant probiotic bacteria by pulsed-field gel electrophoresis. Both left and right are λ ladders (48.5 kb). Lane 1 is strain 786, and lanes 2 to 6 are strain 797.

DETAILED DESCRIPTION OF THE INVENTION

Histologic examination of colonic tissue has revealed no evidence of attachment of *E. coli* O157:H7 to bovine colonic tissue. The rumen appears to be the most important site for long-term carriage of *E. coli* O157:H7. The presence of O157:H7 bacteria in the colon is considered to be a transient state, the bacteria passing through from the rumen source and being shed in feces. Animals can be initially infected by ingestion of contaminated grass, feed or water. Results of the present study demonstrate that *E. coli* O157:H7 persists in the rumens of untreated calves up to 30 days after a single inoculant dose, and is shed in feces throughout the same time period. The O157:H7 bacteria are therefore carried by cattle along with any other microbial strains that inhabit the animals' digestive tract. For purposes of this invention, cattle and other animals in whose tissues or feces *E. coli* O157:H7 can be detected are said to carry *E. coli* O157:H7. The amount of *E. coli* O157:H7 carried by an animal is measurable in various ways, including sampling from various tissues. Most conveniently, the presence of *E. coli* O157:H7 can be

measured in feces. Such measurement is of practical importance, since fecal contamination is the apparent source of meat contamination and also of reintroduction and infection of other animals. As shown herein, the amount of *E. coli* O157:H7 shed in feces is reflected in the amount measurable in rumen. Therefore, the amount of *E. coli* O157:H7 in feces is a measure of the amount carried by the animal. Quantitative measurement of *E. coli* O157:H7 is expressed as colony forming units (CFU) per g feces or per ml rumen.

"Probiotic" is used herein as an adjective to describe bacteria isolated from a natural source and having the property of inhibiting the growth of *E. coli* O157:H7. The test of an inhibition used herein was an *in vitro* test on solid medium in which culture supernatants of candidate isolated bacteria were observed for their property of inhibiting *E. coli* O157:H7 growth when applied to the surface of the solid medium. Typically, a paper disc impregnated with the culture supernatant of a candidate strain was placed on the surface of an agar plate seeded with *E. coli* O157:H7. Probiotic bacterial supernatants caused a ring of clear agar or of reduced growth density indicating inhibition of *E. coli* O157:H7 in the vicinity of the disc. There are other tests for inhibition which are available or could be devised, including direct growth competition tests, *in vitro* or *in vivo* which can generate a panel of probiotic bacteria similar to that described herein. The bacterial strains identified by any such test are within the category of probiotic bacteria, as the term is used herein.

The term "dominant probiotic" is applied to probiotic bacteria which persist in, and are re-isolatable from an animal to which the bacteria have been administered. The criterion used in the work described herein was reisolation 26 days post-inoculation. Bovine calves were fed a mixture of 18 probiotic strains, then from a variety of tissues, digestive contents and feces were sampled 26 days post-inoculation. Four strains were recoverable, designated dominant probiotic strains. Other criteria can be employed, including shorter or longer time periods between inoculation and sampling. It is advisable to choose a time period sufficiently long that persistence of dominant probiotic strains can provide useful reduction of the amount of *E. coli* O157:H7 carried by the animal.

Isolation of dominant probiotic bacteria can be carried out by those of ordinary skill in the art, following the principles and procedures described herein. Of 1200 colonies isolated from cattle feces and tissues, 18 were probiotic and 4 were dominant

probiotic. Therefore, the testing of similar numbers of independent isolates is reasonably likely to successfully yield dominant probiotic bacteria.

Administration of dominant probiotic bacteria can be accomplished by any method likely to introduce the organisms into the digestive tract. The bacteria can be mixed with a carrier and applied to liquid or solid feed or to drinking water. The carrier material should be non-toxic to the bacteria and the animal. Preferably, the carrier contains an ingredient that promotes viability of the bacteria during storage. The bacteria can also be formulated as an inoculant paste to be directly injected into an animal's mouth. The formulation can include added ingredients to improve palatability, improve shelf-life, impart nutritional benefits, and the like. If a reproducible and measured dose is desired, the bacteria can be administered by a rumen cannula, as described herein. The amount of dominant probiotic bacteria to be administered is governed by factors affecting efficacy. In the present study, 10^{10} CFU were administered in a single dose. Lower doses can be effective. When administered in feed or drinking water the dosage can be spread over a period of days or even weeks. The cumulative effect of lower doses administered over several days can be greater than a single dose of 10^{10} CFU. By monitoring the numbers of *E. coli* O157:H7 in feces before, during and after administration of dominant probiotic bacteria, those skilled in the art can readily ascertain the dosage level needed to reduce the amount of *E. coli* O157:H7 carried by the animals. One or more strains of dominant probiotic bacteria can be administered together. A combination of strains can be advantageous because individual animals may differ as to the strain which is most persistent in a given individual.

Dominant probiotic bacteria can be administered as a preventive, to prevent animals not presently carrying *E. coli* O157:H7 from acquiring the strain by exposure to other animals or environments where *E. coli* O157:H7 is present. Young calves and mature animals about to be transferred to a new location, such as a feed lot, are attractive candidates for preventive administration.

Treatment of animals carrying *E. coli* O157:H7 can be accomplished to reduce or eliminate the amount of *E. coli* O157:H7 carried by the animals, by administering dominant probiotic bacteria to *E. coli* O157:H7 infected animals. Animals known to be shedding *E. coli* O157:H7 in feces, or those raised where *E. coli* O157:H7 is known to exist are suitable candidates for treatment with dominant probiotic bacteria.

The methods for administering dominant probiotic bacteria are essentially the same, whether for prevention or treatment. Therefore, the need to first determine whether *E. coli* O157:H7 is being carried by the animals is removed. By routinely administering an effective dose to all the animals of a herd, the risk of contamination by *E. coli* O157:H7 can be substantially reduced or eliminated by a combination of prevention and treatment.

EXAMPLES

Example 1. Isolation of Probiotic Bacteria

Probiotic bacteria were isolated from cattle feces or cattle gastrointestinal tissue (intestine and colon). Fecal samples were collected from cattle that by fecal testing were confirmed negative for *E. coli* O157:H7. Fecal samples were serially diluted (1:10) in 0.1 M phosphate buffer, pH 7.2 (PBS) and 0.1 ml of each dilution was plated on Sorbitol MacConkey agar (SMA) plates. Plates were incubated for 16 h at 37°C and up to ten colonies were randomly selected and each transferred to a test tube containing 10 ml of Trypticase soy broth (TSB) [(BBL, Becton Dickinson, Cockeysville, MD).] Cultures were incubated for 16 h at 37°C. Tissue samples (1 g each) were homogenized (Ultra-Turrax T25 homogenizer, Janke & Kunkel IKA-labortechnik, Germany) at 9,500 rpm for 1 min and then 0.1-ml portions were plated on the surface of SMA plates. Plates were incubated for 16 h at 37°C. Up to 10 colonies were each transferred to test tubes containing 10 ml TSB and incubated for 16 h at 37°C. The supernatant fluid from each culture was filter-sterilized (0.2 µm cellulose acetate membrane, Nalgene Co., Rochester, NY).

Example 2. Screening Cultures for Anti-*E. coli* O157:H7 Properties

A 5-strain mixture of *E. coli* O157:H7, including 932 (human isolate), C7927 (human isolate), E009 (meat isolate), E0018 (cattle isolate), and E0122 (cattle isolate) was used to screen culture supernates for anti-*E. coli* O157:H7 metabolites. Approximately 10^7 *E. coli* O157:H7 of approximately equal populations of each strain in 0.1 ml was surface-plated on duplicate SMA and TSA plates. A disc (12 mm in diameter) was placed on the surface of each SMA and TSA plate and 0.1 ml of filter-sterilized supernatant from a single culture was applied to the surface of the disc. In addition, a disc with 70% ethanol (positive control) and a disc with PBS (negative control) were applied to each plate. The cultures were incubated for 18 h at 37°C and observed for zones of inhibition. A clear zone of more than 1 mm was considered as a positive response.

Example 3. Preparation of *E. coli* O157:H7 Cultures

The same 5-strain mixture described above was used. To facilitate enumeration of these bacterial isolates, the strains were induced for resistance to nalidixic acid (50 µg/ml).

Each strain of nalidixic acid-resistant *E. coli* O157:H7 was transferred into 10 ml of tryptic soy broth (TSB) containing nalidixic acid (50 µg/ml) and incubated for 16-18 h at 37°C with agitation (150 rpm). A 2-ml suspension of each isolate was transferred to 300 ml of TSB. After incubating at 37°C for 16-18 h, the bacteria were sedimented by centrifugation (4,000 x g for 20 min) and washed 3 times in PBS. PBS was added to sedimented bacteria in an amount needed to obtain an optical density (O.D.) of 0.5 at 630 nm (10^8 CFU/ml). A mixture of the 5 isolates (2×10^9 CFU of each strain) of *E. coli* O157:H7 was mixed in 250 ml of 2% sterilized skim milk just prior to oral inoculation of calves. Bacterial populations were confirmed by enumeration on TSA and SMA containing nalidixic acid (50 µg/ml, SMA-NA) plates.

Example 4. Preparation of Probiotic Bacteria

All probiotic bacterial isolates were selected for nalidixic acid resistance (50 µg/ml) for ease of enumeration in feces. The bacteria were grown individually in 10 ml of TSB containing nalidixic acid (50 µg/ml). A 1-ml portion of each isolate was transferred to 100 ml of TSB. After incubating at 37°C for 16-18 h, the bacteria were sedimented by centrifugation, washed, and adjusted to an O.D. at 630 nm of 0.5 using the method described above. The 18 strains of probiotic bacteria (10^{10} CFU) were mixed in 250 ml of 2% sterilized skim milk just prior to oral inoculation of calves. The bacterial population was confirmed by enumeration of serial dilutions on TSA and SMA-NA plates in duplicate.

Example 5. Preparation of Calves

Fifteen single source male dairy calves were reared on milk replacer and weaned at 6 weeks of age prior to transfer to the University of Georgia. Calves were housed individually in climate-controlled BL-2 concrete rooms. Each room had an individual floor drain and was cleaned once daily. Calves were fed a mixture of alfalfa pellets and sweet feed twice daily and had free access to water. During a 2-week conditioning period, feces from all calves were sampled and tested negative, via fluorescent antibody staining, for bovine virus diarrhea, coronavirus, rotavirus, *E. coli* pilus antigens, and *Cryptosporidia*. Fecal floatation for intestinal parasites and bacterial culture for *Salmonella* and *E. coli* O157:H7 was performed and fecal pH was determined. After a 2-

week preconditioning period, calves were surgically fitted with rumen cannulas (flexible rumen cannula). At least 10 days were allowed for surgical recovery and aftercare before the experiment begun.

Example 6. Rumen Cannulation

Feed was withheld from calves for 12 h. The left paralumbar fossa was clipped and scrubbed for standard surgical preparation. The fossa was anesthetized by using a paravertebral nerve block, inverted "L" block; Lidocaine, slightly smaller than the local anesthetic. A circular incision, slightly smaller than the diameter of the cannula, was made and the circular piece of skin and underlying cuticular and external abdominal oblique muscles were removed. Vessels were ligated as necessary and internal abdominal oblique, transverse muscles, and peritoneum were bluntly separated and retracted to create an opening to expose the rumen wall. The rumen wall was grasped with two large towel clamps for traction to exteriorize the rumen. The rumen wall was then sutured to the skin using #3 catgut or vetafil incorporating the muscle layers with a continuous suture pattern. The rumen wall was incised and a circular piece of rumen was removed and the cannula inserted. Calves were treated for 5 days after surgery with procaine penicillin G intramuscularly. The area between the cannula and the rumen wall was gently cleansed daily with betadine solution.

Example 7. Inoculation of Calves

Following a 12 h fast, calves were inoculated via rumen cannulation with 250 ml of skim milk containing probiotic bacteria. After 48 h, the 5- strain mixture of *E. coli* O157:H7 was inoculated via the same route. Control calves were challenged with the 5- strain mixture of *E. coli* O157:H7 only. Following challenge, calves were examined daily for clinical signs including depression, pyrexia, diarrhea, and anorexia. Rectal feces or samples collected from the fuscular tube were determined for pH, and enumeration of *E. coli* O157:H7 and probiotic bacteria.

Isolation and Enumeration of Bacterial Inocula: A sample of 10 g of feces or rumen content was collected through rectum retrieval or rumen cannulation daily after inoculating *E. coli* O157:H7. Samples were placed in a tube containing 15 ml of Cary-Blair transport medium, kept at 5°C, and transported to the Center for Food Safety and Quality Enhancement for analysis. A volume containing 1 g of feces was serially (1:10) diluted in 0.85% NaCl to 10⁻⁶ and 0.1 ml of each dilution was plated in duplicate on

SMA-NA. Tissue samples of the entire gastrointestinal tract collected at necropsy were held at 5°C until analysis. Content of each tissue from each segment was separated and weighed, and the tissue was rinsed with 100 ml of PBS. The rinsed tissue was added to 9 ml of PBS and homogenized for 1 min at 9,500 rpm with an Ultra-Turrax tissue homogenizer. A sample of 0.1 ml tissue or tissue content suspension was inoculated onto SMA-NA plates in quadruplicate and incubated at 37°C for 24 h for enumeration of *E. coli* O157:H7 or probiotic bacteria. If these bacteria were not detected by the direct plating method, a selective enrichment method (17) (modified TSB containing 50 µg nalidixic acid/ml) was performed. Samples were each placed in 100 ml of selective enrichment medium and incubated at 37°C for 24 h with agitation at 150 rpm. Dilutions of cultures were plated on SMA-NA and isolates were selected and further tested. Colonies typical of *E. coli* O157:H7 (sorbitol negative) were replated on SMA-NA and confirmed as *E. coli* by biochemical methods, and as O157 and H7 by serological methods. Probiotic bacteria were confirmed by DNA fingerprinting by pulsed-field gel electrophoresis (PFGE).

Example 8. Genomic Fingerprinting of Bacterial Isolates

PFGE procedures similar to those described previously were used (14). Bacteria were grown in 10 ml of TSB at 37°C for 24 h with agitation at 200 rpm. The bacteria were sedimented by centrifugation (4000 X g, 20 min), washed three times in 75 mM NaCl containing 25 mM EDTA at pH 7.4 (SE), and resuspended in 0.5 ml of SE. The bacterial suspension was mixed with 0.5 ml of 2% (w/v) low melting point agarose in buffer consisting of 10 mM Tris, 10 mM MgCl₂, and 0.1 mM EDTA (TME), pH 7.5. This mixture was dispensed into sample molds and the agarose plugs were digested with proteinase K (2 mg proteinase K, 50 mM Tris, 50 mM EDTA, 1% N-Lauroylsarcosine/ml, pH 8.0) at 56°C overnight. The samples were washed in 10 mM Tris, 5 mM EDTA, pH 7.5 (TE), and digested with 50 U of XbaI. After incubating at 37°C overnight, the reaction was stopped by the addition of 20 µl of 0.5 M EDTA. The DNA samples were electrophoresed on a 1.2% agarose gel in 0.5 X TBE buffer by a contour-clamped homogeneous electric field device (CHEF MAPPER, BioRad). After electrophoresis for 24 h at 200 V with pulse times of 5-50 seconds and linear ramping and an electrical field angle of 120° at 14°C, the gels were stained with ethidium bromide and bands were

visualized and photographed with UV transillumination. The results for 3 dominant probiotic strains, 271, 786 and 797 are shown in Figs. 9 and 10.

Example 9. Necropsy of Calves

Calves were euthanatized with intravenous sodium pentobarbital. The gastrointestinal tract was clamped at the esophagus and rectum and removed in toto. Four to six-cm lengths of duodenum, proximal, middle, and distal jejunum, proximal and distal ileum, proximal and distal cecum, proximal loop of the ascending colon, centripetal turn and centrifugal turn of the spiral colon, transverse colon, and descending colon were double tied to allow sampling of all sections for enumeration of *E. coli* O157:H7 and probiotic bacteria in both the tissue and its content with minimal cross-contamination. Sections and contents of rumen, reticulum, omasum, and abomasum, and sections of kidney, spleen, liver, gall bladder, jejunal lymph node, ileal lymph node, cecal lymph node and tonsil also were collected for culture and enumeration of *E. coli* O157:H7 and/or probiotic bacteria. Sections from all of these sites, as well as sections of prescapular lymph node, skeletal muscle, skin, tonsil, thyroid, thymus, esophagus, heart, pancreas, umbilicus, adrenal, urinary bladder, and testes also were placed in 10% buffered formalin for histologic examination.

Example 10. Histopathology and Immunohistochemistry of Tissues

Fixed tissues were embedded in paraffin by standard methods, sectioned at 5 μ m and stained with hematoxylin and eosin. Selected sections were Gram stained. The sections exhibiting large numbers of surface or luminal bacteria histologically were selected and treated by an alkaline phosphatase immuno-staining procedure to identify *E. coli* O157:H7. Tissues were deparaffinized in xylene for 10 min, rehydrated through graded alcohols, and rinsed in PBS. The sections were covered with *E. coli* O157:H7-specific antibody (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) and incubated in a humidity chamber for 30 min at RT. After a 10-min rinse in PBS, slides were covered with a second antibody labeled with biotin for 20 min in a humidity chamber at room temperature (RT). The slides were rinsed for 10 min in PBS, returned to the humidity chamber, and the tissue sections were covered with alkaline phosphatase-conjugated streptavidin. After incubation at RT for 20 min, the slides were rinsed in PBS for 10 min, placed in the humidity chamber, and overlaid with substrate solution for 15 min. The slides were rinsed in PBS for 10 min, counterstained for 3 min with Mayer's

hematoxylin, mounted with aqueous medium followed by nonaqueous mounting medium, and examined microscopically.

Example 11. Amounts of *E. coli* O157:H7 carried in absence and presence of probiotic bacteria

In vitro screening of potential probiotic bacteria that secrete metabolite(s) inhibitory to *E. coli* O157:H7. Eighteen of 1,200 colonies isolated from cattle tissue and feces inhibited *E. coli* O157:H7 *in vitro*. Among them, five colonies were isolated from feces, five from the small intestine, and eight from the colon. Seventeen of the 18 colonies were identified as *E. coli* and the other as *Proteus mirabilis*. All were assayed for Shiga toxin production and none produced Shiga toxin. PFGE genomic DNA fingerprinting revealed 13 different profiles among the 18 isolates.

Colonization of calves by probiotic bacteria. One calf initially was fed one strain of probiotic bacteria (*E. coli* at 10^{10} CFU). The calf appeared to be normal, and this *E. coli* was recovered by the enrichment procedure from only the ileum and cecum at the termination of the experiment (12 days). Two calves then were fed the entire 18 strains (approximately equal concentrations, 5×10^8 CFU each) of probiotic bacteria (10^{10} CFU/per calf) as a mixture. The calves feces were of normal consistency and the bacteria colonized the gastrointestinal tract for up to 27 days (at termination of the study counts were 50 to 200 CFU/g of feces).

Determination of dominant probiotic bacteria strains by PFGE. Twenty-one colonies isolated from the tonsil, omasum, reticulum, rumen, proximal ileum, distal cecum, proximal loop of ascending colon, transverse colon, and feces at 26 days postinoculation were analyzed by PFGE. Isolates with four DNA profiles were dominant and all were *E. coli*. Among the twenty-one colonies, nine were strain #797, seven were strain #786, three were strain #271, and two were strain #1019.

Pathological changes in calves by probiotic bacteria. Although some strains of the inoculated bacteria were recovered at necropsy from tissue specimens from different parts of the gastrointestinal tract, there were no pathological changes in any of the tissue samples assayed.

Efficiency of probiotic bacteria in reducing carriage of *E. coli* O157:H7 in calves. Of the 9 calves administered only *E. coli* O157:H7, all remained healthy with no evidence of fever or diarrhea. *E. coli* O157:H7 was isolated intermittently from rumen

fluid of all animals during 3 weeks post-inoculation (Fig. 1). Shedding of *E. coli* O157:H7 in feces at various levels was continuous throughout the experiment (mean 28 days) (Fig. 2). At necropsy, *E. coli* O157:H7 was isolated from rumen contents of eight of ten, and from the colon of 10 of 10 calves. No pathological changes were observed in any of the tissue samples examined.

All calves that were administered probiotic bacteria 2 days before treatment with *E. coli* O157:H7 remained healthy with no evidence of fever or diarrhea. *E. coli* O157:H7 was detected in rumen samples collected through the fistula tube, for up to 9 days in two animals, 16 days in one animal, 17 days in two animals, and 29 days in one animal (Fig. 3). *E. coli* O157:H7 was detected in feces for up to 11, 15, 17, 18, 19, and 29 days (at termination of experiment) in each of one animal (Fig. 4). At necropsy (mean 30 days), *E. coli* O157:H7 was not recovered from rumen samples from any of these six animals; however, these bacteria were recovered from the colon of one of the six animals. The *E. coli* O157:H7-positive animal was twice fasted for 2-day periods (day 16, 17 and day 23, 24) postinoculation during the study. Four of the six probiotic-treated animals were fasted according to this protocol.

Example 12. Efficacy of Dominant Probiotic Bacteria as a Treatment for Reducing/Elimination *E. coli* O157:H7 in Cattle

Preparation of Dominant Probiotic Bacteria. Four strains of *E. coli* (271, 797, 786 and 1019) previously determined to be inhibitory of *E. coli* O157:H7, were selected for nalidixic acid resistance (50 µg/ml) for ease of enumeration in feces. Approximately equal populations of each of the four strains were mixed (total 10^{10} CFU) into 50 ml of 2% sterilized skim milk for administration to calves. The *E. coli* populations were confirmed by enumeration on duplicate TSA and SMA-NA plates.

Inoculation of Calves. A total of 16 calves was used. Following a 24-h fast, each was administered a 5-strain mixture of *E. coli* O157:H7 in 50 ml of 2% sterilized skim milk (10^{10} CFU) through a cannula tube. Two calves were treated with probiotic bacteria (10^{10} CFU) through a cannula tube 1 day after administration of *E. coli* O157:H7. Two additional calves were treated with probiotic bacteria (10^{10} CFU) 3 days after administration of *E. coli* O157:H7. Rumen samples collected through the cannula tube and rectal feces were enumerated daily for *E. coli* O157:H7 and probiotic bacteria.

Efficiency of treatment of probiotic bacteria in reducing/eliminating carriage of *E. coli* O157:H7 in calves. Of the 12 calves administered only *E. coli* O157:H7 as positive controls, O157 was isolated intermittently from the rumen for up to 2 weeks from 1 animal, for 3 weeks from 3 animals, and for 4 weeks from 8 animals (Fig. 5).

Continuous shedding of *E. coli* O157:H7 at various levels in the feces of 11 of 12 calves occurred throughout the study (Fig. 6). At necropsy *E. coli* O157:H7 was isolated from rumen contents of 9 of 12 calves and from the colon of 10 of 12 calves.

Four calves were treated with a mixture of four strains of probiotic bacteria (strains 271, 786, 797, and 1019) 1 to 3 days after administering *E. coli* O157:H7. *E. coli* O157:H7 was detected in rumen samples for up to 6 days in 1 animal, 8 days in two, and 9 days in one (Fig. 7). *E. coli* O157:H7 was detected in feces for up to 10 days in two animals, 11 days in one, and 15 days in one (Fig. 8). At necropsy (two at 22 days and two at 27 days), *E. coli* O157:H7 was not recovered from samples of rumen or colon (tissue or contents) from any of these four animals. Only strains 271, 786, and 797 of probiotic bacteria were recovered from the four animals at the end of the study. Strain 1019 was not detected in any of the animals at the time of necropsy.

The foregoing examples illustrate the principles and practice of preventing and treating the carriage of *E. coli* O157:H7 by administering probiotic or dominant probiotic bacteria to an animal carrying *E. coli* O157:H7. Strains 271, 786 and 797 of *E. coli* were isolated and shown to be dominant probiotic bacteria. From the ease of isolation and number of strains obtained, it is evident that other dominant probiotic strains can be isolated and used to inoculate cattle or other animals for preventing or treating carriage of *E. coli* O157:H7. Different strains can be advantageous for different applications depending on animal species, breed, age, diet, living environment and management practices. All such bacterial strains isolated and/or used as generally described herein for effectively reducing or eliminating the amount of *E. coli* O157:H7 carried by an animal are within the scope of the invention. Methods of administration capable of providing an effective dose of probiotic or dominant probiotic bacteria to an animal include a variety of feeding, drinking, and other oral administration methods known to the art, using a variety of formulations containing the bacteria, all within the scope of the invention. All such variations and modifications, based upon or derived from the teachings and disclosures herein are deemed within the scope of the appended claims.

The following strains are deposited with the American Type Culture Collection, pursuant to 37 CFR 1.801-1.809:

E. coli 271 ATCC Accession No. 202020, August 13, 1997

E. coli 786 ATCC Accession No. 202018, August 13, 1997

5 E. coli 797 ATCC Accession No. 202019, August 13, 1997

CLAIMS

1. A microorganism selected from the group of dominant probiotic bacteria consisting of *E. coli* 271, *E. coli* 786, *E. coli* 797 and *E. coli* 1019.
2. A method for selecting probiotic bacteria capable of inhibiting the growth of *E. coli* O157:H7 comprising the steps of:
 - isolating naturally-occurring bacterial strains from animal tissue fluids, digestive contents or feces, producing isolated strains;
 - culturing the isolated strains in liquid or solid media;
 - removing cultured strains from the media to produce culture supernatants;
 - applying each culture supernatant to a specific site on a growth plate seeded with *E. coli* O157:H7, whereby the supernatant of a dominant probiotic bacteria inhibits *E. coli* O157:H7 in a zone near the site;
 - subculturing the probiotic bacteria.
3. A method for selecting dominant probiotic bacteria comprising:
 - administering one or more strains of probiotic bacteria to an animal, and reisolating any reisolatable probiotic bacteria from digestive contents or feces of said animal after a predetermined time, whereby the reisolatable probiotic bacteria are identified as dominant probiotic bacteria.
4. The method of claim 3 wherein the probiotic bacteria are provided with a selectable marker trait.
5. The method of claim 3 wherein the probiotic bacteria are distinguishable from one another by DNA restriction fragment digest patterns.
6. The method of claim 3 wherein the animal is a ruminant.
7. The method of claim 6 wherein the animal is a bovine.
8. A method for preventing or treating carriage of *E. coli* O157:H7 by an animal comprising administering an effective amount of one or more strains of dominant probiotic bacteria to the digestive tract of said animal.
9. The method of claim 8 wherein the dominant probiotic bacteria is selected from the group *E. coli* 271, *E. coli* 786, or *E. coli* 797.
10. The method of claim 8 wherein the dominant probiotic bacteria is administered in a series of doses combined with drinking water.

11. The method of claim 8 wherein the dominant probiotic bacteria is administered in a series of doses combined with feed.
12. The method of claim 8 wherein the animal is a ruminant.
13. The method of claim 12 wherein the animal is a bovine.
- 5 14. An inoculant composition comprising one or more strains of dominant probiotic bacteria and a carrier.
15. The composition of claim 14 wherein the carrier comprises water.
16. The composition of claim 14 wherein the carrier comprises a substance edible by cattle.
- 10 17. The composition of claim 14 wherein the dominant probiotic bacteria are selected from the group *E. coli* 271, *E. coli* 786 or *E. coli* 797.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8

**FIG. 9**

**FIG. 10**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/14793

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 63/00; C12N 1/12, 1/20; C12Q 1/02

US CL : 424/93.4; 435/252.1, 252.8, 29

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.4; 435/252.1, 252.8, 29

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, AGRICOLA, WPIDS

search terms: E.coli O157:H7, probiotic, ruminant, bovine

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	ZHAO et al. Development of a species specific probiotic to prevent/reduce carriage of E.coli O157:H7 in cattle. Annual Report of the Center for Food Safety and Quality Enhancement. August 1995, page 15.	1,2,3,6,7, 8,9,12-17 ----- 4,5,10,11
X -- Y	ZHAO et al. Use of vaccine and biological control techniques to control pathogens in animals used for food. Journal of Food Safety. September 1995, Vol.15, No. 2, pages 193-199, especially abstract.	8,12,13 ----- 9-11
X -- Y	US 5,549,895 A (LYON et al.) 27 August 1996, example I, II; col.7, lines 25-30.	1,2 ----- 14-17

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* *A*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B	earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	
P	document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family

Date of the actual completion of the international search

06 OCTOBER 1998

Date of mailing of the international search report

29 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

VERA AFREMOVA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/14793

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 5,302,388 A (DOYLE et al.) 12 April 1994, col. 12, line 4-20; table 3.	3,4 ----- 5-7
X -- Y	US 3,956,482 A (HAHN et al.) 11 May 1976, col. 1, lines 5-7, col. 15, lines 24-28, example 8.	14-16 ----- 17
X -- Y	US 4,138,498 A (DAS) 06 February 1979, abstract, col. 8, lines 24-25.	14-16 ----- 17
Y	BELL et al. A Multistate outbreak of Escherichia coli 0157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. JAMA. 02 November 1994, Vol. 272, No. 17, pages 1349-1353, especially page 1350.	5
Y	WANG et al. Fate of enterohemorrhagic Escherichia coli 0157:H7 in bovine feces. Applied and Environmental Microbiology, July 1996, Vol. 62, No.7, pages 2567-2570, especially abstract and page 2566.	3-7
X -- Y	WO 96/00233 A1 [CHILDREN'S HOSPITAL AND MEDICAL CENTER] 4 January 1996, example 2.	8,11-13 ----- 9,10